|
|
Post by Hot Christian Stocks on Mar 19, 2014 8:40:39 GMT -5
$PLPL Video of the test Stage 1 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa youtu.be/l8kQqF_dJFQ |
|
|
|
Post by Hot Christian Stocks on Mar 20, 2014 8:34:42 GMT -5
$PLPL Announces Favorable Results for Human Clinical Trial 2014-03-20 09:18 ET SEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced favorable results from a recent human clinical trial involving a topical preparation of its Phytofare Catechin Complex. The study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity. The results, which were released to the company on March 17, stated that Phytofare yielded "statistically significant" results when compared to a baseline product.The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare, to skin patches which were tested at 14, 28, and 42 days. The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%.Both of these measures were deemed "statistically significant" by the researcher. In testing skin hydration, a Corneometer(R) was used to measure the change in the dielectric constant due to skin surface hydration.The study showed the Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product.The study pointed out that skin hydration improved significantly at 28 days and then maintained that level throughout the study. The elastic properties reflect the skin's ability to return to its initial position after deformation and can be effected by chronological- and photo aging of the skin. Skin elasticity was evaluated by means of a Cutometer(R).The study showed an average improvement in skin elasticity of 1% at 42 days, though there was significant inter subject variation which rendered the results inconclusive with a recommendation for a larger sample size and longer duration for a future study. Planda Vice President Jamen Shively commented, "This study validates the last decade of research and illustrate the benefits of enhanced bioavailability.We envision our Phytofare topical formulation serving as the backbone for a host of potential cosmetic products and look forward to sharing the results with our distribution partners as we near release of Phytofare to the market." The company has placed an abstract of the study on its website:www.plandaibiotech.com www.stockwatch.com/News/Item.aspx?bid=U-et54567527-U%3aPLPL-20140320&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 31, 2014 8:29:24 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 1, 2014 8:01:30 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 2, 2014 10:13:58 GMT -5
The first product $PLPL - Planda will bring to the market is Phytofare Catechin Complex, which includes the entire catechin profile derived from green tea. Stages 2 and 3 are also set up to process lemons, which will lead to the introduction of Phytofare Limonoid Glycoside Complex later in the year.Citrus bioflavonoids are highly regarded not only for treating cold and flu symptoms but also as a potent anti-inflammatory useful for soft-tissue injuries and sports recovery www.stockwatch.com/News/Item.aspx?bid=U-et1796556585-U%3aPLPL-20140401&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Apr 3, 2014 8:26:43 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 4, 2014 7:40:37 GMT -5
$PLPL Closer to Unzipping the Magic of Phytofare in New Facility NEW YORK, NY -- (Marketwired) -- 04/04/14 Plandaí Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandaí recently finished the all-important Stage 2 on the Senteeko Tea Estate in South Africa. It's this section of the factory that CEO Roger Duffield says "the magic of Phytofare" takes place. Plandaí will make its money and its mark in the biotechnology sector here as it's where the proprietary hydrodynamic sheering process will takes place. Plandaí and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. In order to develop these highly bioavailable extracts, it requires Plandaí's unique extraction process that uses live plant material grown on the tea estate and a combination of temperature and a unique wave of acoustic energy to release the living phytonutrients, rearranging the polyenes into a bio-compatible form. Plandaí's CEO said of this process, "The magic of Phytofare involves unzipping the molecule to release the valuable phytonutrients, which we have now done for the first time on an industrial scale." So, with stage 1 and 2 done, the company has turned to completing stage 3, the only section remaining between Plandaí and the introduction of its Phytofare extracts to the public. The third stage of Plandaí's process separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form. As Plandaí reaches the finish line on the production facility, Duffield said, "It is exciting to see the culmination of over ten years of research and effort on the part of countless supporters." www.stockwatch.com/News/Item.aspx?bid=U-i1104126-U%3aPLPL-20140404&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Apr 7, 2014 8:39:34 GMT -5
So, with stage 1 and 2 done, $PLPL - has turned to completing stage 3, the only section remaining between Plandaí and the introduction of its Phytofare extracts to the public. The third stage of Plandaí's process separates out the solids and any unnecessary elements, rendering pharmaceutical-grade, purified catechins in mainly nano-particle form www.stockwatch.com/News/Item.aspx?bid=U-i1104126-U%3aPLPL-20140404&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Apr 8, 2014 8:01:48 GMT -5
$PLPL Qualifies for Grant From South African Department of Trade & Industry 2014-04-08 08:55 ET - News Release SEATTLE, WA(eTeligis.com) Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May. According to the DTI website (http://www.thedti.gov.za/about_dti.jsp), their strategic objective is to facilitate transformation of the economy to promote industrial development, investment, competitiveness and employment creation. The grant for which Planda qualifies is based on a fixed percentage of actual capital invested in the project. Depending on the final cost of the Senteeko manufacturing facility and the percentage of award as determined by the legislature, the grant is expected to be between 14-26 million Rands ($1.3-2.5 million US). The final amount is expected to be determined over the coming 90 days with the award being paid later in 2014. Chairman and Chief Executive Officer Roger Duffield commented, "The South African government has been among our strongest supporters, first with the $13 million government-backed loan from the Land and Agriculture Bank, and now with an additional $1.3 to $2.5 million grant to help defray the cost of building our production facility. It is a testament to their belief not only in our technology but also our efforts to revitalize the region by creating jobs and operating under a zero carbon footprint model. The grant money will be useful in supporting our operations as the factory comes online and sales begin to ramp up in the coming months." Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity. About Planda Biotechnology, Inc. Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit www.plandaibiotech.comwww.stockwatch.com/News/Item.aspx?bid=U-et971018422-U%3aPLPL-20140408&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Apr 9, 2014 7:48:07 GMT -5
$PLPL - Planda first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids that will also be extracted at the Senteeko facility using lemons bought from neighboring farms until its own lemon trees reach maturity. www.stockwatch.com/News/Item.aspx?bid=U-et971018422-U%3aPLPL-20140408&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Apr 10, 2014 8:25:35 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 11, 2014 8:15:14 GMT -5
$PLPL Plandai Biotechnology's Cannabis Extracts Could Further Shape Marijuana Debate NEW YORK, NY -- (Marketwired) -- 04/11/14 Plandaí Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandaí and its extracts could go a long way toward changing the minds of the drug's opponents. In the survey, 54 percent of respondents favored legalizing the use of marijuana which is a dramatic change from just 4 years ago when in the same survey, only 41 percent thought pot should be legal. Make no mistake about it attitudes are shifting in favor of marijuana in this country, and recent interest is likely due to CNN Chief Medical Correspondent Sanjay Gupta's "Weed" documentaries that are educating more Americans on the realities of cannabis. "Weed" documentaries can be seen commercial free at www.stockmarketmediagroup.com/media. Dr.Gupta himself was once a staunch opponent of legalizing marijuana, but he has since become a strong advocate for the use of cannabis. In those documentaries, Dr. Gupta has highlighted just how powerful the use of cannabinoids can be as a treatment for such things as seizures, pain management, cancer and many others. Plandaí produces highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and will explore the use of both THC and cannabinoids to develop extracts and to pursue various pharmaceutical and nutraceutical applications. Dr. Gupta and a majority of Americans in general agree with Plandaí's CEO Roger Duffield who said, "The medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore." www.stockwatch.com/News/Item.aspx?bid=U-i1106142-U%3aPLPL-20140411&symbol=PLPL®ion=U |
|
